Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation - PMC
AKT signaling is modulated by a complex network of regulatory proteins and is commonly deregulated in cancer. Here, we present a dual mechanism of AKT regulation by the ERBB receptor feedback inhibitor 1 (ERRFI1). We show that in cells expressing ...
Abstract AKT signaling is modulated by a complex network of regulatory proteins and is commonly deregulated in cancer. Here, we present a dual mechanism of AKT regulation by the ERBB receptor feedback inhibitor 1 (ERRFI1). We show that in cells expressing high levels of EGFR, ERRF1 inhibits growth and enhances responses to chemotherapy. This is mediated in part through the negative regulation of AKT signaling by direct ERRFI1‐dependent inhibition of EGFR. In cells expressing low levels of EGFR, ERRFI1 positively modulates AKT signaling by interfering with the interaction of the inactivating…
related reading
- Molecular Medicine Reportsspandidos-publications.com
- Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance - PMCncbi.nlm.nih.gov
- Gene 33/Mig6/ERRFI1, an Adapter Protein with Complex Functions in Cell Biology and Human Diseases - PMCpmc.ncbi.nlm.nih.gov
- Epigenetic regulation during cancer transitions across 11 tumour typesnature.com
- Loss and revival of androgen receptor signaling in advanced prostate cancernature.com
- Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma modelpmc.ncbi.nlm.nih.gov
- The current state of the art and future trends in RAS-targeted cancer therapiesnature.com
- The novel mechanism of lenalidomide activity - PMCncbi.nlm.nih.gov
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemianature.com
- Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancernature.com
- CNIH4: a novel biomarker connected with poor prognosis and cell proliferation in patients with lower-grade gliomapmc.ncbi.nlm.nih.gov
- RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia - PubMedpubmed.ncbi.nlm.nih.gov